Researchers tested whether low-dose Retatrutide (Reta) (a triple incretin agonist) could slow cancer growth independent of weight loss, using a mouse model of pancreatic ductal adenocarcinoma (PDAC) in diet-induced obese mice.
Mice were implanted with pancreatic tumor cells and split into four treatment groups:
Treatments were given once every three days for two weeks after tumors were established.
Low-dose Reta reduced tumor volume by ~3-fold compared with control mice.
Anti-PD-1 therapy reduced tumors by ~5-fold.
The combination of Reta + anti-PD-1 showed about a 4-fold reduction, but did not significantly outperform either treatment alone.
Mouse body weight remained stable across groups during treatment — meaning the anti-tumor effects were not driven by weight loss.
Blood glucose was significantly lower in Reta-treated mice, suggesting engagement of metabolic pathways.
The fact that Reta slowed tumor growth without causing weight loss suggests it may act through:
Direct effects on tumor cells and/orModulation of immune responses or metabolism inside the tumor microenvironment.
The researchers measured immune cells in the spleen at the end of the study, indicating they were exploring potential immunological mechanisms, though details were not in the abstract.
Retatrutide at low, non-weight-loss doses had anti-cancer activity comparable to anti-PD-1 therapy in this mouse model of pancreatic cancer.
Combination therapy didn’t clearly add benefit over either treatment alone.
These results suggest retatrutide could be explored as a novel anti-tumor treatment, especially for obesity-associated cancers, potentially through metabolic or immune pathways beyond its weight-loss effects.
For more information on the clinical study – Click Here
Study Overview Researchers tested whether low-dose Retatrutide (Reta) (a triple incretin agonist) could slow cancer growth independent of weight loss,
The American opioid crisis has inspired a new generation of regenerative research. This includes exploring peptides for pain management. Due
Enter retatrutide (LY3437943), a novel triple hormone receptor agonist developed by Eli Lilly, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1
Key Points: Nicotinamide adenine dinucleotide (NAD+) is found in every cell, serving as an essential cofactor — the compounds necessary
What Are Your Mitochondria? Mitochondria are often called the “powerhouses” of your cells. These tiny, double-membraned organelles are responsible for
GLP-1 receptor agonists are peptides that have become a big focus in weight loss and metabolic health research. These compounds
